Patches could improve adherence to HIV PrEP

To address the concerns of HIV and unplanned pregnancy, researchers are developing multipurpose prevention technologies (MPTs) that aim to reduce women’s risks of HIV and provide effective contraception.

A promising mechanism for MPT delivery is via microarray patches (MAPs). MAPs are an easy-to-use, self-administered, discreet delivery technology that could improve adherence to HIV PrEP and access to long-acting contraceptives.

PATH partnered with Genesis to assess MAPs technology in South Africa, while CHDC conducted a parallel study in Uganda. The combined results have now been published in PLoS ONE. Insights from end users and other stakeholders will guide MAPs' development for HIV PrEP and as a MPT, ensuring they meet the needs of the end user and fit into the healthcare system.